GlassScriptPhysician profile
Anup K Lahiry
NPI 1083694954
$7,155.79
in general payments reported to CMS, 2019-2025
48 companies · $79.35 in 2025
The $79.35 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $1,231 · 2021: $1,682 · 2022: $2,181 · 2023: $320 · 2024: $206 · 2025: $79.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $306 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $305.96 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $878.39 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $651.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $533.88 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $495.84 | 2019-2022 | |
| Genentech USA, INC. | $299.21 | 2019-2022 | |
| Amgen INC. | $287.38 | 2019-2022 | |
| Daiichi Sankyo INC. | $278.69 | 2019-2022 | |
| Eisai INC. | $258.38 | 2019-2024 | |
| Incyte Corporation | $253.23 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $221.79 | 2019-2023 | Imbruvica |
| Seagen INC. | $215.59 | 2019-2022 | |
| Glaxosmithkline, LLC. | $198.68 | 2020-2024 | Jemperli, Zejula, Pediarix |
| Abbvie INC. | $187.50 | 2019-2025 | |
| Celgene Corporation | $178.56 | 2020-2022 | |
| Janssen Biotech, INC. | $174.72 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anup Lahiry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.